Larimar Therapeutics, Inc.
nomlabofusp
Friedreich's ataxia
Resolved
7days ago
Phase 2 readout Β· ~ Jun 30, 2026 estimated
What's at stake
Phase 2 trial results for nomlabofusp in Friedreich's ataxia are due ~ Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
Β· SEC 8-K
verified 14h ago
βTopline open label study data to support BLA submission expected in Q2 2026.β